Cancer Advances Announces Allowance of a New Patent
News Jul 15, 2013
Cancer Advances, Inc. (Cancer Advances), a wholly owned, biotechnology portfolio company of Cato BioVentures, announces the allowance of a new patent. The newly released patent covers monoclonal antibodies to the gastrin hormone and has been allowed in Canada. This patent is an additive to Cancer Advances’ suite of products that work to inhibit the cancer promoting hormone, gastrin.
Cancer Advances has developed an intellectual property portfolio that currently holds over 100 United States and worldwide patents related to a lead compound, Polyclonal Antibody Stimulator (PAS) that has been clinically studied in three gastrointestinal cancers. PAS is an active immunotherapeutic that induces antibodies against the hormone, gastrin 17 (G17), and its precursor, (gly)G17, of which there is extensive published evidence for a central role of both of these endogenous compounds in the development and progression of gastrointestinal tumors, as well as other tumors.
The monoclonal antibodies to gastrin hormone patent cover a pharmaceutical composition, comprised of a humanized monoclonal antibody to gastrin. This patent also covers a method of diagnosing, preventing or treating a gastrin-mediated disease or condition. Combined with Cancer Advances’ already extensive arsenal of patents, this newly allowed patent will help in the fight against gastrin-mediated diseases.